EZH2 and acute myeloid leukemia: In addition to that PRC2/EZH2 can inhibit downstream key targets such as KDM5B, with this process blocking the recruitment and/or assembly of oncogene suppression complexes (including HDAC-containing SIN3B and NuRD or other gene-repressive complexes) to maintain the oncogenicity of NUP98-NSD1+ AML (Ren et al., 2022).